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a b s t r a c t
Understanding the pharmacokinetics, blood compatibility, biodistribution and clearance properties of
nanoparticles is of great importance to their translation to clinical application. In this paper we report
the biodistribution and pharmacokinetic properties of tobacco mosaic virus (TMV) in the forms of
30018 nm2 rods and 54 nm-sized spheres. The availability of rods and spheres made of the same
protein provides a unique scaffold to study the effect of nanoparticle shape on in vivo fate. For enhanced
biocompatibility, we also considered a PEGylated formulation. Overall, the versions of nanoparticles
exhibited comparable in vivo proﬁles; a few differences were noted: data indicate that rods circulate
longer than spheres, illustrating the effect that shape plays on circulation. Also, PEGylation increased
circulation times. We found that macrophages in the liver and spleen cleared the TMV rods and spheres
from circulation. In the spleen, the viral nanoparticles trafﬁcked through the marginal zone before
eventually co-localizing in B-cell follicles. TMV rods and spheres were cleared from the liver and spleen
within days with no apparent changes in histology, it was noted that spheres are more rapidly cleared
from tissues compared to rods. Further, blood biocompatibility was supported, as none of the
formulations induced clotting or hemolysis. This work lays the foundation for further application and
tailoring of TMV for biomedical applications.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Nanoparticles hold great potential for clinical research and
application for diagnosing and treating diseases (Parveen et al.,
2012). Nanoparticles are used to deliver a high payload of cargo,
such as imaging and therapeutic compounds, to speciﬁc sites of
disease while avoiding healthy tissue. While receptor-speciﬁc
ligands can direct these nanoparticles to target speciﬁc cells and
tissues, a majority of the injected dose is cleared by the reticu-
loendothelial system (RES) and mononuclear phagocyte system
(MPS) (Zhu et al., 2013). On the road toward clinical translation of
any nanoparticle platform, a detailed understanding of the body’s
response to the nanoparticles is required; this will allow tailoring
and optimizing biodistribution and clearance.
Viral nanoparticles (VNPs) are protein-based, nanoscale
materials designed by nature to deliver cargos to cells; being
natural experts at cargo delivery led to their study and applica-
tion as drug and contrast agent delivery vehicles. There are a
number of reasons that make VNPs excellent platforms for
applications in biomedicine, including their biocompatibility,
biodegradability, high monodispersity, and ease of production
and functionalization. Platform simplicity and high processabil-
ity are key components for clinical translation of nanoparticle
platforms – VNPs offer this through their genetic engineering
capabilities and simple puriﬁcation protocols. A library of VNPs
is available and currently under investigation for clinical appli-
cations. These include the plant viruses cowpea mosaic virus
(CPMV) and potato virus X (PVX), as well as bacteriophages such
as M13 and P22 (Yildiz et al., 2011). For example, it has been
demonstrated that 30 nm-sized icosahdral CPMV target tumor
cells and the inﬂamed endothelium in atherosclerotic plaques,
based on its natural interactions with cell surface expressed
vimentin (Steinmetz et al., 2011; Plummer et al., 2012). Also,
targeting ligands speciﬁc to the vascular endothelial growth
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factor receptor-1 or gastrin-releasing peptide receptors have
been used to re-direct CPMV to tumor endothelial cells and
cancer cells in preclinical mouse models (Steinmetz et al., 2011;
Brunel et al., 2010). Recent data indicate that in addition to
tailoring the VNP surface chemistry (Wu et al., 2012), VNP shape
can also be used as a handle to tailor biodistribution and tissue
penetration properties (Gandra et al., 2012; Shukla et al., 2013;
Lee et al., 2013). For example, we showed that ﬁlamentous PVX
has enhanced passive tumor homing and deeper tissue penetra-
tion compared to icosahedral CPMV nanoparticles. While both
platforms were cleared by MPS and accumulated in liver and
spleen, differences were noted: PVX was mostly retained in the
spleen, and CPMV in the liver (Shukla et al., 2013). However, it
should be noted that besides the shape-derived differences, PVX
and CPMV also differ in their protein make up. Therefore, in this
work, we turned toward the evaluation of biodistribution and
clearance of VNP-based materials of identical protein make up
but different shape, speciﬁcally the rods and spheres, of tobacco
mosaic virus (TMV).
TMV is a rod-shaped VNP measuring 300 nm in length, 18 nm in
diameter and a 4 nm-wide interior channel; its structure is known to
atomic resolution (Klug, 1999). This stiff rod-shaped nanoparticle has
been utilized as a material for a variety of applications in nanotech-
nology (Soto and Ratna, 2010; Liu et al., 2012). Chemically and
genetically engineered TMV particles have been developed and
tested for applications as light harvesting systems (Miller et al.,
2007, 2010), energy storage (Chen et al., 2010), sensing (Bruckman
et al., 2010), cell growth (Kaur et al., 2010; Bruckman et al., 2008),
magnetic resonance imaging contrast enhancement (Bruckman et al.,
2013), and vaccine development (Koo et al., 1999; Fitchen et al., 1995;
McCormick et al., 2006a, 2006b). Recently Atabekov et al. (2011) have
shown that TMV can undergo thermal transition to form RNA-free
spherical nanoparticles (SNPs). The thermal denaturation of TMV
rods yields insoluble coat proteins that somewhat surprisingly
associate with each other to assemble into highly stable SNPs. The
size of the TMV SNPs can be tightly tuned through adjustment of the
protein concentration: at higher concentration (10 mg/mL), up to
800 nm-sized SNPs are formed, and at lower concentrations (0.1 mg/
mL), SNPs as small as 50 nm are formed (Atabekov et al., 2011).
Further, it was shown that SNPs can be coated with a variety of
polymers and proteins (Nikitin et al., 2011). Following electrostatic
binding, formaldehyde can bond the proteins to the SNP surface.
Protein-functionalized SNPs are under development for vaccines
(Karpova et al., 2012).
To us, the TMV rods and SNPs provide an interesting platform
to investigate the impact of shape on biodistribution and clear-
ance. We would like to acknowledge that the TMV rods and
spheres are not identical in their structural properties: while the
TMV rod consists of a helical arrangement of precisely arranged
coat proteins, the SNPs consist of aggregated, most likely dena-
tured, coat proteins. Nevertheless, the TMV rods and SNPs are
made up of the same proteins and zeta potential measurements
support that the rods and spheres have comparable surface charge
(see results). Therefore, we reasoned, that the TMV rod and SNP
platform would be suitable tools for investigation of their in vivo
properties. This is also important considering that several groups
have turned toward the development of the platforms for poten-
tial applications in medicine and materials (see above).
Here, we report the study of TMV and SNP biodistribution,
clearance, and blood compatibility in mice. The application of rods
and spheres allow us to provide further insights into the impact of
shape on the in vivo fate of nanoparticles. Further, we investigated
the effect of PEGylation: native and PEGylated TMV rods were
studied. PEG was applied because of its known properties to
enhance solubility and biocompatibility of intravenously adminis-
tered nanoparticles (Albanese et al., 2012).
Results
Properties of TMV-based nanorods and nanoparticles Cy5-TMV,
PEG-Cy5-TMV, and Cy5-SNP
TMVwas produced at yields of 4.5 mg pure TMV per 1 g infected
plant material using a 1-day puriﬁcation protocol (Leberman,
1966). Three different TMV-based nanoparticle formulations were
produced for evaluation of biodistribution, pharmacokinetics, and
blood compatibility in mice. Previously established bioconjugation
and thermal transition protocols were used to produce dye-labeled
TMV rods (Cy5-TMV), PEG2000-coated dye-labeled TMV rods (PEG-
Cy5-TMV), and dye-labeled TMV spheres (Cy5-SNPs) (Fig. 1). In
brief, TMV rods were labeled with Cy5 (and PEG2000) at exterior
tyrosine residues (TYR139) using a two-step diazonium coupling
and copper catalyzed azide alkyne cycloaddition (CuAAC) reaction
protocol. Dye-labeled SNPs were obtained by heating interior Cy5-
labeled TMV particles for 15 s at 96 1C (Bruckman et al., 2013).
Interior labeling of the TMV rod is accomplished by labeling GLU97
and GLU106 with an alkyne handle followed by CuAAC chemistry
protocols to introduce the ﬂuorophores. (Bioconjugation methods
for modiﬁcation of SNPs are currently under development in our
laboratory, however, not yet fully implemented. Therefore it was
not possible to study PEGylated SNPs.)
The resulting Cy5-labeled (and PEGylated) TMV rods and SNPs
were characterized for labeling efﬁciency, size, morphology, and
surface properties using a combination of transmission and scan-
ning electron microscopy (TEM and SEM), dynamic light scattering
(DLS), UV-Vis absorbance, gel electrophoresis (SDS-PAGE), size
exclusion chromatography (SEC), zeta potential, and MALDI-TOF
MS. UV–vis absorbance conﬁrmed the attachment of about 900
Cy5 dyes per Cy5-TMV and PEG-Cy5-TMV; this equates to a
labeling efﬁciency of 50%, meaning that every second Tyr
residue was modiﬁed with a Cy5 dye (a single 300 nm-long TMV
rod is comprised of 2130 identical copies of one coat protein).
About 600 Cy5 dyes were conjugated to SNPs, meaning that 15% of
the 4260 interior glutamic acids per TMV were modiﬁed. The
lower labeling efﬁciency may be explained by steric hindrance and
lower accessibility of the interior versus exterior surface. Based on
MALDI-TOF MS and SDS-PAGE lane analysis (Fig. 2), we estimated
coverage of PEG-Cy5-TMV with approximately 400 PEG2000
chains/TMV, which equates to a labeling efﬁciency of 20%.
TEM (Fig. 2) and SEM images (not shown) conﬁrmed the
structural integrity of the particle formulations. It should be noted
that based on the length of the RNA-genome, fully-assembled TMV
nanorods have a length of 300 nm (and a width of 18 nm with a
4 nm-wide interior channel). A distribution of lengths is observed
inTEM imaging,which could be explained by the fact that intermediate
states as well as broken TMV rods are observed in TEM imaging. SNPs
were measured at 54714 nm based on TEM and 8376 nm based on
DLS (Fig. 2). Based on themeasured protein concentration and SNP size
observed,we estimate that each SNP is formedbya single TMVrod. This
is also in good agreement with the volume of a TMV cylinder and
sphere composed of the same number of proteins.
Finally, the zeta potentials of Cy5-TMV, PEG-Cy5-TMV, and Cy5-
SNP were determined at 18, 17, 10 mV, respectively (Fig. 2).
The slightly lower zeta potential for SNPs is attributed to the loss
of RNA following thermal transition.
Pharmacokinetics of TMV rods and SNPs differs
Plasma circulation half-life was determined in healthy Balb/c
mice after intravenous bolus injection of 10 mg/kg Cy5-labeled
(and PEGylated) TMV/SNP formulation (Fig. 3). The ﬂuorescence of
plasma spiked with known TMV and SNP concentrations was
measured to establish a standard curve, which was used to
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determine the percent-injected dose (%ID) in circulation. For
pharmacokinetic analysis of nanoparticles, the following mathe-
matical models are most commonly used: non-compartmental in
which the area under the curve is considered, compartmentalized
one-phase in which one considers the body as one blood pool with
no organs, and compartmentalized two-phase in which one con-
siders a quick circulating blood pool and slower blood ﬂow in
organs. We analyzed and ﬁtted our data for these models and
found that the TMV and SNP pharmacokinetics best ﬁt according
to the compartmentalized two-phase clearance mechanism. The
ﬁrst phase is characterized by a quick clearance, achieved through
tissue distribution (liver and spleen), referred to as the distribution
or equilibrium phase. The longer second phase involves a more
active metabolic clearance mechanism and is referred to as the
elimination phase. The phase I half-life for Cy5-TMV, PEG-Cy5-
TMV, and Cy5-SNP were calculated at 3.5, 6.3, and 2.3 min,
respectively, phase II values were 94.9, 44.4, and 58.2 min,
respectively. Data indicate that PEGylation of TMV rods doubles
the phase I half-life. Furthermore, shape appears to have a
signiﬁcant impact: the percent-injected dose of elongated Cy5-
TMV and PEG-Cy5-TMV rods remaining in circulation is signiﬁ-
cantly higher compared to the amount of Cy5-SNPs remaining in
circulation (20% ID TMV rods versus 5% ID SNP Fig. 3, inset).
Blood biocompatibility: TMV and SNP formulations do not induce
hemolysis or blood clotting
The blood compatibility of TMV rods and SNPs was tested
utilizing two general assays: red blood cell (RBC) disruption (hemo-
lysis) and blood coagulation. Hemolysis was measured by incubat-
ing puriﬁed RBCs with TMV/SNP formulations. The incubation ratio
of 2.5 mg/mL TMV to 5108 RBCs/mL represents a roughly 1000
higher ratio of nanoparticles to RBCs compared to the injected dose
used for in vivo studies (mouse blood contains 10109 RBCs/mL).
Following a 1-h incubation, RBCswere pelleted and the hemoglobin
content – which is released after RBC lysis – was measured by
reading the absorbance at 540 nm (Fig. 4A and B). Data indicate that
none of the formulations tested induced hemolysis.
Next, the effect of TMV/SNP formulations on blood clotting
parameters was measured using rotational thromboelastometry
(ROTEM). The ROTEM test utilized a whole-blood sample, with no
platelet or coagulation activating agents added. In the present
study, mean changes in the sum of clotting time and clot forma-
tion time (CTþCFT) and the maximum clot ﬁrmness (MCF) in the
presence of TMV/SNP formulations differed no more than 5% from
the saline baseline, suggesting a negligible impact of the nano-
particles on the coagulation mechanism (Fig. 4C and D).
Biodistribution and clearance: SNPs and TMV show broad organ
distribution, but SNPs show faster tissue clearance
The organ biodistribution for Cy5-TMV, PEG-Cy5-TMV, and
Cy5-SNP was determined after intravenous tail vein injection of
10 mg/kg TMV/SNP and subsequent sacriﬁce of healthy Balb/c
mice at 4, 24, and 96 h. Following perfusion, we collected the
heart, liver, kidney, spleen, lungs, brain, and stomach for ﬂuores-
cence analysis (Fig. 5). The biodistribution is reported in percent-
injected dose per gram of tissue (%ID/g), which was determined
based on standard curves using homogenized organs spiked with
TMV/SNP of known concentration. The biodistribution proﬁle for
each nanoparticle formulation followed the same trend: the
majority of TMV, PEGylated TMV and SNPs accumulated in liver
and spleen. Differences were noted in the clearance proﬁles: while
rod-shaped TMV and PEGylated TMV was still detectable in liver
and spleen 24 h post-administration, SNP formulations appeared
to be cleared from tissues within 1 day. Data are consistent with
Fig. 1. (A) A PyMol generated schematic representation of the thermal transition of tobacco mosaic virus (TMV) rods to spherical nanoparticles (SNPs). Several coat proteins
have been removed from the TMV rod to highlight the hollow interior with interior glutamic acids, GLU97 and GLU106, in blue and exterior tyrosine, TYR139, in red.
(B) Schematic illustration of the bioconjugation reactions used to incorporate sulfo-Cy5 dyes and PEG2000 molecules on the exterior of TMV rods. (C) Schematic illustration
showing the method to generate sulfo-Cy5 labeled SNPs.
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immunoﬂuorescence imaging of sectioned tissues (see below and
supporting information).
Immunoﬂuorescence imaging of liver- and spleen-sections
The majority of TMV and SNPs were deposited in liver and
spleen; therefore we sought to analyze these tissues further and
prepared cryosections for immunoﬂuorescence analysis and co-
localization studies with macrophages (F4/80 marker), B-cells
(B220 marker), and T-cells (CD3 marker). Within the liver sections,
Cy5-TMV, PEG-Cy5-TMV, and Cy5-SNP were found to be co-
localized with macrophage marker F4/80 (Fig. 6, Supporting
Table 1, and Supporting Figs. 5–7), which is consistent with
clearance of the proteinaceous nanoparticle formulations via the
mononuclear phagocytotic system (MPS). Consistent with data
reported by ﬂuorescence assay, SNPs appeared to be cleared from
liver macrophages faster compared to TMV rods (independent of
PEGylation).
Distribution in the spleen followed a different pattern: at the
4-h time point TMV rods and SNPs were co-localized with the
marginal zone macrophages surrounding the spleen’s B-cell folli-
cles. At 24 and 96 h post-administration, the TMV and SNP signals
appear to be co-localized with B-cell stain marker B220 (Fig. 6,
Supporting Table 1, and Supporting Figs. 5–7). We noticed sig-
niﬁcantly less TMV/SNP signal in B-cell follicles at 96 h versus 24 h,
which is consistent with quantitative biodistribution data and may
indicate tissue clearance (loss of ﬂuorescent signal however
cannot be ruled out, see discussion). Although quantitative data
(see Fig. 5) indicate clearance of SNPs from the spleen by 24 h
post-administration, some signal was still apparent in confocal
microscopy (Fig. 6). Co-localization with T-cell marker or increased
activation of T-cells was not apparent in any of our studies
(Supporting Figs. 8 and 9).
Fig. 2. Characterization of Cy5-TMV, PEG-Cy5-TMV, and Cy5-SNPs. (A) Transmission electron micrograph images of TMV rods and SNPs. (B) Size exclusion chromatographs of
PEG-Cy5-TMV and Cy5-TMV. (C) A table comparing the charge, size and number of Cy5 dyes per particle. (D) MALDI-TOF MS spectra of native-TMV, Cy5-TMV, PEG-Cy5-TMV,
and Cy5-SNP. (E) SDS-PAGE of (lane 1) native-TMV, (lane 2) Cy5-TMV, (lane 3) PEG-Cy5-TMV, and (lane 4) Cy5-SNP. The (a) unmodiﬁed 18 kDa TMV coat protein, (b) Cy5
modiﬁed 19 kDa coat protein, and (c) PEG modiﬁed 20 kDa coat proteins are identiﬁed for reference (it should be noted that only a ratio of the coat proteins were
modiﬁed, see Discussion section).
Fig. 3. Pharmacokinetics of Cy5-TMV, PEG-Cy5-TMV, and Cy5-SNP. At least three
data points were collected for each time point and formulation; averages and
standard deviations are shown. Data were analyzed using Prism software, and data
are reported as percentage injected dose against time.
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No pathological changes were noted based on histological
examination of tissues
Histological examination of tissues comparing PBS and TMV/
SNP-inoculated animals included livers and spleens 4, 24, 96 h,
and 14 days post-administration of TMV and SNP formulations.
No pathological changes were noted. Microscopic ﬁndings were
similar between TMV/SNP-inoculated and control animals, with no
signs of overt toxicity and inﬂammation, such as tissue degenera-
tion, apoptosis, or necrosis in any of the examined tissues
(Supporting Figs. 1–4).
Discussion
The shape, size, and surface properties of nanoparticles inﬂu-
ence their in vivo behaviors, such as circulation half-life, biodis-
tribution, and clearance mechanism (Sa et al., 2012; Li and Huang,
2008; Longmire et al., 2011). Shielding strategies, such as PEGyla-
tion, of nanoparticles is often effective to increase circulation half-
life by reducing opsonization and lowering mononuclear phago-
cyte recognition. Furthermore, recent research indicates that
elongated nanomaterials with high aspect ratio (aspect ratio is
deﬁned as length divided by width) have demonstrated some
beneﬁcial in vivo properties for biomedical applications, such as
enhanced margination for improved endothelial targeting (Lee
et al., 2009; Gentile et al., 2008; Decuzzi and Ferrari, 2006), and
most importantly, evasion of macrophages leading to prolonged
circulation (Decuzzi et al., 2010).
In this work, we studied biodistribution, biocompatibility, and
clearance of TMV in mice. Rod-shaped TMV and spherical SNPs as
well as PEGylated formulations were considered to address the
following fundamental questions: ﬁrst, whether nanoparticle shape
impacts the in vivo fate of TMV and second, whether PEGylation
would enhance pharmacokinetics and alter biodistribution. The data
gained lay a foundation for the further development and application of
TMV for biomedical applications, such as imaging and drug delivery.
Overall, the data indicate clearance of TMV by liver and spleen,
irrespective of shape and surface coating (i.e. PEG). Comparing
spherical versus rod-shaped TMV, differences were noted: SNPs show
shorter circulation and appear to be cleared more rapidly from tissues.
The TMV-based formulations show good blood biocompatibility;
further immunohistochemistry indicated that TMV does not induce
adverse effects in tissues (however, more detailed organ-function
assays would need to be conducted to further support this observa-
tion). Within liver and spleen TMV and SNPs localize within macro-
phages and B-cells, which is consistent with clearance by the RES and
MPS, and may also indicate immunogenic processing of the proteinac-
eous nanoparticle.
Polymer coating of nanoparticles to create a stealth layer is
an accepted strategy to improve circulation half-life (Storm et al.,
1995). The most popular stealth coating is polyethylene glycol
(PEG) (Perry et al, 2012). PEG provides a neutral charged hydro-
philic layer that reduces opsonization by serum proteins leading to
lowered recognition by MPS of the RES (Owens and Peppas, 2006;
Knop et al., 2010). While there are no reports comparing the
pharmacokinetics of native and PEGylated VNPs; this has been
demonstrated using various other nanoparticles. For example, the
circulation half-life of hydrogel nanoparticles (80 nm80 nm
320 nm) increased from 0.89 h to 19.5 h after application of a thick
coating (brush morphology) of PEG5000 (Perry et al., 2012). Here,
we have demonstrated that TMV rods coated with a low-density
PEG2000 layer increased the circulation half-life from 3.6 to
6.6 min; therefore potentially allowing a majority of the injected
particles to interact with a diseased area an additional 30 times
(10 cycles/min).
Fig. 4. Blood biocompatibility assays. (A) Red blood cell (RBC) hemolysis assay. (B) Zoomed in RBC hemolysis assay showing Cy5-TMV, PEG-Cy5-TMV, and Cy5-SNP do not
lyse RBCs. (C) Effect of Cy5-TMV, PEG-Cy5-TMV, and Cy5-SNP on clotting (normalized to saline control), measured in rotational thromboelastometry (ROTEM). There were no
signiﬁcant changes in the combined clotting time (CTþCFT) and maximum clot ﬁrmness (MCF) compared to the saline control (dotted line). Error bars represent S.D.
M.A. Bruckman et al. / Virology 449 (2014) 163–173 167
To assess whether TMV-based nanoparticles remain structu-
rally sound upon intravenous administration, we assessed their
stability in plasma. In brief, TMV nanorods were incubated in
native and heat-inactivated plasma, collected by ultrapelleting,
and analyzed by TEM imaging, which conﬁrmed the presence of
intact TMV rods (Supporting Fig. 10). Considering the mild envir-
onment in blood (average salt concentration of 140 mM with a
pH of 7.4) it is not surprising the TMV remain structurally sound.
Both TMV and SNPs withstand a range of temperature, pH, and salt
conditions. Furthermore, the lack of detectable signals from the
kidneys indicate that disassembly into coat proteins upon intra-
venous administration is unlikely (based on the low molecular
weight and small size, free coat proteins would be cleared through
the kidneys, while assembled high molecular weight complexes
are expected to be cleared by the MPS, as observed).
While PEG-coating increased the circulation time of TMV, it should
be noted that shape-derived effects were even more profound: a
signiﬁcantly higher dose of TMV rods remains in circulation over
longer time periods compared to SNPs. At 60 min post i.v. adminis-
tration of TMV versus SNP, 20% ID TMV remained in circulation, while
only 5% ID SNPs were detected. This is reﬂected by the increased phase
II half-lives of 94.9 min for TMV and 58.2 min for SNPs. This
phenomenon has been reported using various synthetic nanoparticle
systems: for example synthetic polymeric ﬁlomicelles show enhanced
circulation compared to spherical micelles made of the same polymer,
and could be explained by the fact that the high aspect ratio materials
are less likely taken up by MPS (Geng et al., 2007). There is increasing
supporting data showing that elongated particles avoid clearance by
phagocytosis because of their larger and more complex contact angles
between the nanoparticle and phagocytotic cell (Albanese et al., 2012).
This has been demonstrated with gold nanoparticles where the
circulation half-life of rods was signiﬁcantly longer than their spherical
shaped counterpart (Arnida et al., 2011).
Tailoring the circulation times is critical for successful clinical
application; for example, the circulation times must be carefully
adjusted in imaging applications to ensure fast accumulation of
the contrast agent at the target site, followed by rapid clearance.
On the other hand, enhanced circulation times may be desired
for tumor homing and drug delivery. Passive tumor homing is
achieved making use of the enhanced permeability and retention
(EPR) effect, and it is indicated that enhanced circulation of
PEGylating nanoparticles increase tumor homing (Geng et al.,
2007). Indeed, it has been shown that PEGylated CPMV shows
enhanced tumor homing compared to native CPMV (Steinmetz,
2010). Similarly, PEGylated bacteriophage MS2 successfully tar-
geted breast cancer tumors, demonstrating the versatility and
utility of PEGylation to cancer targeting (Farkas et al., 2013). For
other diseases requiring active targeting, such as arterial inﬂam-
mation, longer circulation times provide more chances for the
targeted nanoparticle to interact with its target (Sen Gupta, 2011).
We hypothesize that pharmacokinetics of SNPs and TMV rods
could be further enhanced through enhanced PEGylation, or by
application of different PEG conformations. The conformation of
PEG chains could either be mushroom or brush, and is determined
based on the dimension of the PEG and its grafting density. The
size of PEG is characterized by its Flory radius (RF¼αN3/5), where α
is the length of one monomer, 0.35 nm, and N is the number of
monomers per polymer chain. The grafting density is given by the
distance (D) separating each PEG molecule (De Gennes, 1987;
Wattendorf and Merkle, 2008). A low density of PEG molecules
form the mushroom conformation and is roughly deﬁned where
RFoD. When RF4D, the brush conformation dominates. PEG in
the brush conformation is more effective at shielding of nanopar-
ticles from opsonization compared to PEG in the mushroom
conformation. Although, reports have shown that, even when in
mushroom conformation, PEG will still act as an effective shield,
but to a lesser degree than in the brush conformation (Perry et al.,
2012; Steinmetz and Manchester, 2009). Data indicate that TMV
rods were labeled with 400 PEG2000 molecules per 300 nm rod
(20% of coat proteins). The low loading yields a PEG density (A) of
39.8 nm2/PEG (A¼surface area of TMV/number of PEGs). From
here, we can estimate the distance (D) separating each PEG




). Here, PEG2000 has an
RFE3.5 and therefore at this density, the PEG molecules will be
in the mushroom conformation (because RFoD). In order for
PEG2000 to form the brush conformation on TMV, we would need
at least 85% of the coat proteins to have PEG2000 molecules
attached. Alternatively, higher molecular weight PEG (at least
5000) could be used; for example, only 30% coating of TMV rods
is required to achieve RF4D leading to brush conformation.
VNPs are particularly interesting for biomedical applications
because they are considered biocompatible, biodegradable, and
nonhazardous towards humans (Yildiz et al., 2011). Researchers
have reported in vivo fate of spherical VNPs cowpea mosaic virus
(CPMV) (Rae et al., 2005; Singh et al., 2007), cowpea chlorotic
mottle virus (CCMV) (Kaiser et al., 2007), bacteriophages Qβ
(Prasuhn et al., 2008), and MS2 (Farkas et al., 2013) and ﬁlamen-
tous potato virus X (PVX) (Shukla et al., 2013). For each system
studied, RES clearance and deposition of VNPs in liver and spleen
was observed, as indicated by sequestration by blood monocytes,
dendritic cells and tissue macrophages. Overall, the reported
biodistribution of plant viruses and bacteriophages follows a
similar trend and is in agreement with the biodistribution of
Fig. 5. Tissue biodistribution of (A) Cy5-TMV, (B) PEG-Cy5-TMV, and (C) Cy5-SNP at
4, 24, and 96 h after i.v. injection. Three female Balb/c animals were analyzed per
time point and formulations. Averages and standard deviations are shown.
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TMV and SNP reported here. The accumulation of nanoparticles
in the liver and spleen 4 h post-injection is also consistent with
the tissue distribution of other nanoparticle formulations (Li and
Huang, 2008).
The cryosectioning analysis indicates high colocalization of
TMV particles (Cy5-TMV, PEG-Cy5-TMV, Cy5-SNP) with liver
macrophages (Kupffer cells) at 4 h. This is consistent with previous
reports that Kupffer cells are the primary clearance mechanism for
nanoparticles in circulation (Sadauskas et al., 2007). Data indicate
that the rod-shaped particles (Cy5-TMV and PEG-Cy5-TMV)
undergo hepatobiliary processing followed by excretion from the
body within 24–96 h. It is interesting to note that SNPs appear to
follow much faster tissue clearance. SNPs were no longer detected
24 h post-administration. This is presumably due to the less stable
structure of the SNPs, allowing a faster breakdown and removal
from the tissue. The coat proteins of the rods are held tightly
together by the single-strand RNA embedded in its structure.
Formation of spheres removes the RNA and the SNPs are held
together only by protein–protein interactions. The faster tissue
clearance of SNPs may reduce potential toxic side effects, particu-
larly when delivering toxic therapeutic cargos or contrast agents.
Quick hepatobiliary clearance of nanoparticles is critical and
remains a critical barrier to translation of nanoparticle systems.
Hard inorganic nanoparticles, such as single-walled carbon nano-
tubes (SWNTs), gold, and silica, are secreted slowly after uptake in
the liver and spleen. It can up to 2 months for SWNTs to be cleared
from mice (Liu et al., 2008). Other hard nanoparticles also remain
in RES organs for even longer times, such as gold, which leads to
Fig. 6. Immunoﬂuorescence imaging of liver and spleen sections 4, 24, and 96 h after i.v. administration of (A) Cy5-TMV, (B) PEG-Cy5-TMV, and (C) Cy5-SNP (colored green).
Liver sections were stained for macrophages marker F4/80 (red). Spleen sections were stained for B-cell marker B220 (red) and macrophage marker F4/80 (red).
The marginal zone, and B-cell follicles are highlighted in the spleen sections (in A) for reference. Cell nuclei are stained with DAPI (blue). Inset into each image is the
Manders' M2 colocalization coefﬁcient (M2¼1.0 is attributed to 100% colocalization). Data were analyzed using ImageJ software. Scale bars¼250 μm.
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unwanted toxic effects in these organs (Gad et al., 2013). The fast
clearance of the protein-based VNPs thus may offer a signiﬁcant
advantage over synthetic nanoparticles.
Nanoparticle toxicity is a signiﬁcant concern for a variety of
nanoparticles due to their long retention times (Gad et al., 2013;
Khlebtsov and Dykman, 2011). The toxic effects of long-term
retention of nanoparticles in organs include inﬂammation and
apoptosis. In agreement with rather fast tissue clearance, H&E-
stained livers and spleens did not indicate signs of overt toxicity
and inﬂammation, such as tissue degeneration, apoptosis, or
necrosis in any of the examined tissues, thus further supporting
biocompatibility of the TMV platform.
The spleen’s role in the body is to act as a blood ﬁlter, removing
and replacing worn out red blood cells, and it is the center of
activity in the RES system. The spleen is made up of two distinct
zones – red pulp and white pulp – with a marginal zone made up
of antigen presenting cells bordering these areas. The red pulp
contains nearly half of the body’s monocytes and is where some
TMV particles initially accumulate after ﬁltration through this
organ. Our results imply that a signiﬁcant amount of TMV particles
are ﬁltered to the marginal zone for presentation to the lymphoid
white pulp. B-cells in the white pulp then accept the TMV particles
over time and presumably synthesize antibodies, since TMV is a
foreign material. Localization of TMV particles with B-cell follicles
is characteristic of a humoral immune response (Murakami et al.,
2007; Bachmann, 1998). Interestingly, the PEG shielding did not
affect the outcome of rod-shaped TMV in the spleen. As men-
tioned previously, the PEG shielding on these particles is low
density, meaning that a more optimized formulation may lead to
better splenic avoidance and a decrease in potential immune
response.
In an effort to conﬁrm the biocompatibility of TMV particles, blood
hemolysis and coagulation assays were performed. Both assays
performed indicated blood biocompatibility of TMV rods and spheres.
Increases or decreases in blood coagulation could lead to serious side
effects such as increased cardiovascular events or bleeding out. An
increase or decrease in clotting times would therefore indicate the
nanoparticles activated or deactivated platelets or factors within the
coagulation system. An increase or decrease in clot ﬁrmness would
indicate that the particles affect primarily the interaction of the
ﬁbrinogen and platelets (Siller-Matula et al., 2008). Previous groups
have observed signiﬁcant effects of particle/microbead treatments on
ROTEM-measured clotting times in the range of 10–70% change from
baseline controls (Shoffstall et al., 2013; Zipperle et al., 2013). Here,
there was negligible difference in the parameters studied, therefore
suggesting that TMV particles do not directly interfere with the
coagulation mechanism, neither do they induce cell lysis, and there-
fore the data provide additional support indicating biocompatibility.
Viruses were discovered more than 100 years ago; in fact, TMV
was the ﬁrst virus to be discovered and studied. Classical virology has
long focused on the understanding of virus structure and virus–host
interactions, and advances in virology have led to signiﬁcant advances
in structural biology, genetics, medicine, and related disciplines.
The ﬁeld of applied virology has attracted chemists and engineers;
who started to approach viruses from a different perspective and see
them as platforms, as nanostructured materials providing a three-
dimensional scaffold for controlled arrangement of functional mole-
cules. This led to the design, development, and testing of virus-based
materials for potential commercialization in devices (e.g., batteries and
storage devices), as well as delivery vehicles for medical imaging, drug
delivery, and vaccines. The ﬁeld has grown out of its infancy, and the
utility of virus-based materials is emerging. To realize a potential
clinical application, detailed understanding of the in vivo properties
must be gained.
It is generally understood that plant viruses are part of the food
chain and found in many crops and vegetables; they are
considered safe (Colson et al., 2010). Speciﬁc to this report, TMV
particles are found in nearly all cigarettes, and recently were found
in the saliva of cigarette smokers (Balique et al., 2012). Further
investigation of TMV in humans revealed that antibodies against
TMV are prevalent in the population (Liu et al., 2013) with smokers
developing higher concentrations of these antibodies. Although
reports indicate that TMV may be entering human cells, it is not
replicating (Balique et al., 2013), further supporting the develop-
ment of TMV as a medical cargo delivery vehicle. The application
of plant viruses in the medical sector is becoming a growing ﬁeld
of interest and impact; therefore, more extensive investigation
into the interaction of plant viruses, speciﬁcally TMV, in the body
is required. Toward this goal, we provided a thorough analysis and
discussion of the in vivo proﬁle of rod-shaped and spherical TMV
nanoparticles. Although differences were noted, all three formula-
tions (SNP, TMV, PEG-TMV) followed a similar the overall trend
regarding blood compatibility, pharmacokinetics, biodistribution,
and clearance: TMV-based materials do not induce apparent toxic
effects and show fast plasma and tissue clearance proﬁles, desired
properties for medical cargo delivery vehicles.
Conclusion
TMV rods measuring 30018 nm2 were engineered to include
ﬂuorescent Cy5 dyes for imaging and injected as is (Cy5-TMV)
or with a PEG coating (PEG-Cy5-TMV). We thermally transitioned
Cy5-TMV rods into 50 nm spherical particles (Cy5-SNP) to test
the effect of shape without changing the surface properties (same
coat protein make-up). We found that the rod-shaped particles
have a longer circulation half-life compared to spheres and that
PEGylation also increased the circulation half-life. Mononuclear
phagocytes in RES organs, i.e. the liver and the spleen, clear each
particle formulation. The plasma clearance and tissue response is
typical for protein-based nanoparticles, and nanoparticle in gen-
eral. Future studies set out to investigate the immune response
further; as TMV and SNPs were found to be co-localized with
B-cells indicating activation of the immune response. Overall TMV
rods and spheres follow typical biodistribution and fast tissue
clearance, the latter is important and provides an advantage over
synthetic nanoparticle formulations, which may persist in cells
and tissues over long time periods. Our data indicate blood and
tissue biocompatibility, as toxic effects were not apparent. Giving
the data reported here, in combination with the particle proper-
ties, high aspect ratio, multivalency, TMV fulﬁlls various require-
ments according to emerging design rules that are being explored
in nanomedical engineering (Wen et al., 2013). This work sets the




TMV was produced in Nicotiana benthamiana plants; 6–8 weeks
after seeding, plants were infected through mechanical inocula-
tion. Infected leaves were harvested 14–21 days after infection
and stored at 80 1C. TMV was extracted in yields of 4.5 mg/g of
infected leaf material using established methods (Leberman,
1966). TMV concentration was determined using UV–vis absor-
bance (ε at 260 nm¼3.0 mg1 mL cm1), and virus particle struc-
tural integrity was conﬁrmed using transmission electron
microscopy (TEM) and size exclusion chromatography (SEC) (see
below).
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Synthesis of Cy5-TMV and PEG-Cy5-TMV
All reagents were purchased from Fisher Scientiﬁc unless
otherwise speciﬁed. The following protocols were modiﬁed from
established methods (Bruckman et al., 2013). Brieﬂy, TMV was
decorated with terminal alkynes at external Tyr side chains by
reaction with an in situ generated diazonium salt (3-ethynylaniline
mixed with sodium nitrite in an acidic solution). Next, TMV
rods underwent a copper-catalyzed azide-alkyne cycloaddition
(CuAAC) reaction by reacting either 2 M equivalents of sulfo-Cy5-
azide (Lumiprobe) for Cy5-TMV or 2 M equivalents of sulfo-Cy5-
azide and 2 M equivalents of azide-mPEG2000 (Nanocs Inc.) for
PEG-Cy5-TMV with the exterior alkyne TMV (eAlk-TMV). Reactions
were performed in 10 mM phosphate buffer at pH 7.0 with TMV
(2 mg/mL), copper sulfate (1 mM), sodium ascorbate (2 mM), and
aminoguanidine (2 mM) for 30 min on ice. The reaction mix was
puriﬁed using a 10–40% sucrose gradient (made using a Biocomp
Instruments Gradient Master) and ultracentrifugation and ana-
lyzed by TEM, SEC, and MALDI-TOF MS (see below).
Synthesis of Cy5-SNP
Fluorescent SNPs were produced by ﬁrst labeling TMV rods
with Cy5 dyes on their interior channel followed by thermal
transitioning to SNPs. Interior Cy5 labeling was adapted from a
previously reported protocol (Bruckman et al., 2013). Brieﬂy,
to a solution of TMV (2 mg/mL) in 100 mM HEPES buffer pH 7.4,
propargyl amine (2.7 mM), ethyldimethylaminopropylcarbodii-
mide (4.8 mM), and n-hydroxybenzotriazole (4.8 mM) was added
to label interior glutamic acid residues; the reaction was incubated
for 24 h at room temperature. The reaction was puriﬁed by sucrose
cushion ultracentrifugation. Next, the interior alkynes underwent
CuAAC reaction with sulfo-Cy5-azide (2 M equivalents) using the
procedure stated above. SNPs were generated trough heat trans-
formation using a solution of 0.05 mg/mL TMV containing 0.5%
PEG (w/v) in distilled H2O. SNPs were formed using a PCR
thermocycler with the following program: 4 1C for 5 min, 96 1C
for 15 s, 4 1C for 10 min. SNPs were then concentrated using spin
ﬁlter concentrators. SNP protein concentration was determined
by SDS-PAGE lane analysis (ImageJ) and UV–vis absorbance at
260 nm. The size and morphology of SNPs were conﬁrmed by
TEM, SEM, and dynamic light scattering (DLS).
Transmission and scanning electron microscopy (TEM and SEM)
For TEM, formvar carbon ﬁlm coated copper TEM grids (Elec-
tron Microscopy Sciences) were ﬂoated on drops of TMV rods or
SNPs (20 μL, 0.1 mg/mL) for 2 min, washed with DI water, and
negatively stained with 2% (w/v) uranyl acetate in DI water for
2 min. Samples were examined using a Zeiss Libra 200FE trans-
mission electron microscope operated at 200 kV. For SEM, samples
were dried onto 55 mm2 silicon wafers (Ted Pella, Inc.) and then
mounted on the surface of an aluminum pin stub with use of
double-sided adhesive carbon discs (Agar Scientiﬁc). The stubs
were then sputter-coated with gold in a high-resolution sputter
coater (Agar Scientiﬁc, Ltd.) and transferred to a Hitachi 4500
scanning electron microscope operated at 5 kV.
Size exclusion chromatography (SEC)
All particles were analyzed by SEC using a Superose6 column
on the ÄKTA Explorer chromatography system (GE Healthcare).
Samples (100 μL, 1.0 mg/mL) were analyzed at absorbance wave-
lengths of 260, 280, and 647 nm at a ﬂow rate of 0.5 mL/min using
0.1 M potassium phosphate buffer pH 7.0.
Zeta potential analysis
The zeta potential for each sample was determined by placing a
0.01 mg/mL solution of sample in a 90Plus particle size analyzer
(Brookhaven Instruments Corporation).
MALDI-TOF MS analysis
For MALDI-TOF MS analysis, native and modiﬁed TMV were
denatured by adding 6 μL guanidine hydrochloride (6 M) to 24 μL
sample (o1 mg/mL) in DI water and mixing for 5 min at room
temperature. Denatured proteins were spotted on MTP 384
massive target plate using Zip-TipsμC18 (Millipore). MALDI-TOF
MS analysis was performed using a Bruker Ultra-Flex I TOF/TOF
mass spectrometer.
Gel electrophoresis
Denaturing gel electrophoresis was used to analyze protein
subunits, speciﬁcally proteins were analyzed on denaturing 4–12%
NuPAGE gels (Invitrogen) using 1 MOPS running buffer (Invitro-
gen) and 10 μg of sample. After separation, the gel was photo-
graphed using an AlphaImager (Biosciences) imaging system after
staining with Coomassie Blue. ImageJ software (rsbweb.nih.gov/ij/,
Supporting Information) was used for band analysis and to
determine the protein concentration per SNP.
Animals
All experiments were carried out in accordance to the Case
Western Reserve University’s Institutional Animal Care and Use
Committee. Female Balb/c mice were used for all experiments.
Ten to 14-week old animals were used for all studies, and mice
were maintained on an alfalfa-free diet (Teklad) for at least
2 weeks prior to viral nanoparticle administration via tail vein
injection.
Pharmacokinetics studies
Modiﬁed TMV and SNPs were administered intravenously via
the tail vein at a dosage of 10 mg/kg body weight. Blood was
collected by orbital sinus bleeds and cardiac puncture. Blood
samples were collected at 3, 5, 10, 15, 20, 30, 40, 60, 80, 100,
200, 400, and 1400 min (n¼3 for each time point). The samples
were centrifuged for 15 min at 7000 rpm in a tabletop centrifuge
to remove blood cells from plasma. The plasma was analyzed using
a ﬂuorescence plate reader (λEx 600 nm and λEm 665 nm). Data
were analyzed using Prism software.
Hemolysis assay
Blood was collected and pooled from three Balb/c mice. Within
1 h of collection, pooled blood was centrifuged at 500g for 10 min,
the supernatant was removed and calcium/magnesium-free DPBS
(HyClone) was added to reach previous volume. Centrifugation
was repeated two or more times at 1000g for 10 min. The red
blood cells (RBCs) were counted and diluted to 1109 cells/mL in
Ca/Mg free DPBS. Twenty microliter of RBCs were mixed with
20 μL sample and incubated in 37 1C water bath for 1 h. Samples
tested: (PEGylated) TMV and SNP (5 mg/mL), DPBS was used for a
negative control, and 1% (v/v) Triton X-100 was used as a positive
control. Solutions were centrifuged for 10 min at 1000g to remove
intact RBCs. The absorbance of the resulting supernatant was
tested at 540 nm for hemoglobin content on a Thermo Scientiﬁc
NanoDrop 2000 Spectrophotometer. Percent hemolysis was
M.A. Bruckman et al. / Virology 449 (2014) 163–173 171
calculated by dividing the sample absorbance by the absorbance
achieved with 1% Triton X-100.
Coagulation assay
Coagulation assays were performed in citrated whole blood
(3.8% sodium citrate; 1:9 ratio; obtained via cardiac puncture from
anesthetized Sprague Dawley rats). Thromboelastometry measure-
ments were run using a Gamma ROTEM (Rotem Inc., Durham, NC),
using the company’s non-activated (NATEM) test in the presence
of either saline or the viral nanoparticles (5 mg/mL). The outcomes
considered included the standard ROTEM parameters clotting time
(CT), clot formation time (CFT), the sum of the two (CTþCFT), and
maximum clot ﬁrmness (MCF). CT is deﬁned as the time from the
start of the assay until the initial clotting is detected (thick-
ness¼2 mm). CFT is deﬁned as the time between clot initiation
until a clot thickness of 20 mm is detected. MCF is deﬁned as the
maximum thickness (in mm) that a clot reaches during the
duration of the test (Siller-Matula et al., 2008). The study was
performed using blood samples from 3 rats and each sample was
normalized to a saline control. Statistical analysis was performed
using a one-way ANOVA of the raw data (not normalized), with a
Dunnett’s comparison test between treatment groups and the
saline control.
Biodistribution analysis
Ten to 14 week old Balb/c mice were injected with a dose
of 10 mg/kg modiﬁed TMV/SNP via the tail vein. The mice were
sacriﬁced at 4, 24, and 96 h, perfused with PBS, and the heart,
brain, lung, spleen, liver, kidneys, and stomach, were collected
(n¼3 animals for each time point). The organs were cut in half and
one half placed in a tube and plunged in liquid nitrogen and stored
at 80 1C. The frozen organs were thawed and mixed with PBS
(100 mg organ/mL PBS). They were then homogenized and cen-
trifuged at 7500g for 10 min, 2 times to remove tissue debris; the
supernatant was measured for ﬂuorescence intensity using a
ﬂuorescence plate reader (λEx 600 nm and λEm 665 nm). The
second half of the organs were embedded in OCT media for
cryo-sectioning and immunohistochemistry and -ﬂuorescence
studies (see below).
Immunohistochemistry and -ﬂuorescence
Embedded organs were sectioned at 10 μm using a Leica CM 1850
cryostat. The frozen sections were then ﬁxed with 95% ethanol for
10 min at 20 1C, blocked with 10% (v/v) goat serum in DPBS for 1 h
at room temperature. After washing with DPBS, the primary antibody
was bound for 1 h at room temperature in 1% (v/v) goat serum in
DPBS. The primary antibodies used here were F4/80 (Biolegend, stains
macrophages), FITC-B220 (Biolegend, stains B-Cells), and CD3 (Biole-
gend, stains T-Cells); 250:1 dilutions were used for all antibodies. The
F4/80 and CD3 antibodies required a secondary antibody for ﬂuores-
cence imaging, Alexa Fluor 488 or 555-labeled secondary antibodies
(Invitrogen) were used, 250:1 dilutions were used. Finally, cell nuclei
were stained using DAPI (Sigma) diluted 9500:1 for 20 min. Slides
were mounted and analyzed using a Fluoview FV1000 (Olympus)
confocal microscope.
H&E histology
Embedded organs were sectioned at 10 μm using a Leica CM
1850 cryostat. The frozen sections were ﬁxed with 95% ethanol for
5 min at 20 1C then air-dried. After washing with DI water, the
slides were stained with hematoxylin (Richard-Allen Scientiﬁc)
for 45 s. The tissues were washed with 70%, 80%, and 100% ethanol
for 3 min each, sequentially, then stained with eosin for 1 min. The
tissues were mounted and analyzed with a Zeiss Observer.Z1
inverted microscope.
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